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Background: The use of optimized delivery devices has been shown to enhance the potency of DNA vaccines.
However, further optimization of DNA vaccine delivery is needed for this vaccine modality to ultimately be
efficacious in humans.
Methods: Herein we evaluated antigen expression and immunogenicity after intradermal delivery of different doses of
DNA vaccines by needle or by the Biojector jet-injection device, with or without the addition of electroporation (EP).
Results: Neither needle injection augmented by EP nor Biojector alone could induce higher magnitudes of immune
responses after immunizations with a high dose of DNA. After division of a defined DNA dose into multiple skin sites,
the humoral response was particularly enhanced by Biojector while cellular responses were particularly enhanced by
EP. Furthermore, a close correlation between in vivo antigen expression and cell-mediated as well as humoral immune
responses was observed.
Conclusions: These results show that two optimized DNA vaccine delivery devices can act together to overcome dose
restrictions of plasmid DNA vaccines.
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Plasmid-based DNA vaccines are commonly used in vac-
cine research to induce immune responses against infec-
tious agents or tumor antigens. These vaccines possess
advantages including rapid construction and high stabil-
ity, as well as the capacity to induce cellular immune
responses owing to the intracellular production of the
encoded antigen [1]. Still, further optimization of DNA
vaccine delivery is needed for this vaccine modality to
ultimately be efficacious in humans [2,3].
One strategy to influence the immune responses to
DNA vaccines is by the choice of immunization route. We
have chosen to employ intradermal (id) immunizations as
the skin, unlike muscle tissue, has a large population of
resident antigen presenting cells (APCs) that can facilitate* Correspondence: david.hallengard@ki.se
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The skin is also a more accessible tissue than muscle,
allowing for less painful DNA vaccine delivery and facili-
tating studies of in vivo protein expression. In addition to
conventional needle immunization, several injection
devices including Biojector and in vivo electroporation
(EP) are being used to improve DNA delivery to the skin.
Biojector is a CO2-propelled needle-free device that injects
DNA plasmids as a highly focused liquid stream into the
skin. This has been shown to enhance antigen expression
as compared to conventional needle injection [6], most
probably due to the large area and thus larger number of
cells being targeted by injection with Biojector. DNA
vaccine delivery by Biojector has been shown to induce
strong immune responses in preclinical and clinical
trials [6-11].
Another commonly used strategy employed to aug-
ment DNA vaccine delivery is EP. EP enhances transfec-
tion efficacy by the transient formation of pores in thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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mids into the cell. Additionally, the electric pulses result
in an influx of APCs to the site of injection [12,13],
further augmenting the immunogenicity of the gene
product. Thus, EP can significantly enhance expression
[13,14] and immunogenicity [15-18] of plasmid-encoded
antigens.
Similar to other vaccine modalities, the DNA vaccine
dose influences immunogenicity, and immune responses
are generally enhanced by increasing the dose [12,19-22].
Still, an upper limit in terms of in vivo expression [23-26]
and immunogenicity [27,28] has been observed in mice
after intramuscular (im) and id injections. This plateau
appears at doses of 5–100 μg DNA delivered at concentra-
tions ranging between 0.3-2 μg/μl. Limitations in cellular
uptake of plasmids and clearance of antigen expressing
cells by immune cells [29-33] have been suggested to ac-
count for this phenomenon. One way to override this
issue is by dividing the plasmid dose at several injection
sites rather than a single location [9-11,25,28]. Using too
many injections may however limit the feasibility, making
plasmid vaccines less attractive for use in the clinic. It has
also been shown that protein expression can be enhanced
when increasing the plasmid concentration [34,35], sug-
gesting that an increase in plasmid concentration can be
an alternative to large volumes and multiple injections of
DNA vaccines.
In this study we evaluated the capacity of different
id DNA immunization strategies to induce immune
responses in mice. DNA was delivered by needle
or Biojector, with or without the addition of EP.
Luciferase- and HIV-1 Gag-encoding plasmids of vari-
ous concentrations were used in order to determine
the impact of DNA dose on in vivo expression and
immunogenicity in mice, respectively. To avoid dose
limitations by volume restrictions when delivering
DNA vaccines id, we used plasmid preparations of up
to 10 μg/μl. The study showed that a high dose of
DNA injected by Biojector alone (1000 μg) or needle
plus EP (100 μg) induced similar levels of immune
responses as a considerably lower dose of DNA
(10 μg) administered in the same manner. Interest-
ingly, when we combined Biojector-injection with EP,
this dose plateau could be circumvented as evidenced
by the significantly stronger immune responses that
were induced after immunization with the high dose
DNA as compared to the lower dose. Furthermore, a
close correlation between the level of in vivo antigen
expression and frequency of cell-mediated immune
responses, and between reduction in in vivo antigen
expression and magnitude of CD8+ T cell responses,
were observed. These data suggest that a combination
of Biojector and EP could overcome dose restrictions
observed also for other DNA encoded antigens.Methods
Vaccine formulation and immunizations
pKCMVp37B [10,36], pVax-Luc [13] and empty pKCMV
were used for immunizations. Plasmids were amplified
in E. Coli and purified using endotoxin-free GigaPrep
(QIAGEN, Hilden, Germany) and PlasmidSelect (GE
Healthcare) kit. The eluted and precipitated DNA was
dissolved in saline at 4°C overnight to obtain DNA of
10 μg/μl. Gel-clot tests for detecting endotoxins in DNA
preparations were performed at APL Pharma Specials
(Stockholm, Sweden).
Female BALB/c mice (Charles River Laboratories,
Sülzfeld, Germany), 5–8 weeks old, were held at the
Astrid Fagraeus Laboratory (Ethical approval Dnr:
N210/07). Mice were immunized once or twice (week 0
and 4) id on the back of the mouse. Doses of 10–1000 μg
DNA were injected with a 29 gauge Micro-Fine™ needle
(BD, NJ, USA) or by Biojector [10] (Bioject Medical Tech-
nologies, OR, USA) with dermal spacer, with 10 and
100 μl DNA solutions diluted in saline, respectively. The
Biojector was adjusted for delivery to mice (3400 PSI).
Immunizations with needle and Biojector were either
given alone or followed by EP using the Derma Vax™ EP
device (Cellectis, Romainville, France) as previously
described [13]. Briefly, the needle electrodes (2 mm) were
inserted in the shaved mouse skin to cover the injection
site and two pulses of 1125 V/cm (50 μs duration) plus
eight pulses of 275 V/cm (10 ms duration) were applied.
Cellular immune responses
Mice were sacrificed two weeks after the last immunization
or, for the in vivo imaging study, 25 days after a single
immunization, and spleens and serum were collected. Sple-
nocytes were purified by Ficoll-Paque separation (GE
Healthcare, Stockholm, Sweden) and IFN-γ ELISpot and
IFN-γ/IL-2 FluoroSpot assays (Mabtech, Nacka Strand,
Sweden) were performed according to the manufacturer’s
protocol and as previously described [37]. 1×105 viable
cells were plated per well and stimulated with a peptide
pool covering Gag p24B (15mers with ten amino acids
overlap) or the H2-Kd restricted AMQMLKETI (Gag) and
GFQSMYTFV (luciferase) [38] peptides. The final concen-
tration of peptides was 5 μg/peptide/ml.
Antibody responses
Binding antibody titers were assessed with ELISA as pre-
viously described [39]. Plates were coated with 100 μl/
well of 1 μg/ml recombinant Gag p17/p24B (NIBSC/
CFAR, Potters Bar, UK) or recombinant luciferase (Pro-
mega, WI, USA).
In vivo expression
Subsequent to DNA injections, mice were injected intra-
peritoneally (ip) with luciferin potassium salt (Caliper
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assessed by using the IVIS200 apparatus (Xenogen, CA,
USA) as previously described [13]. In the present study,
in vivo expression was assessed ten minutes after ip in-
jection with luciferin and injections with different doses
of pVax-Luc and pKCMVp37B were compared with the
corresponding dose of empty pKCMV plasmid.
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism 4 software (GraphPad Software, CA, USA). A
two-tailed Mann–Whitney test and a Spearman rank
test were used to analyze differences between two
groups and correlation between in vivo expression and
immunogenicity.
Results and discussion
High and low plasmid dose administered by Biojector or
needle followed by EP induce similar levels of immune
responses
The first study was designed to compare id vaccine de-
livery by Biojector with id needle injections augmented
by EP, and evaluate whether a high dose vaccine plasmid
(1000 μg for Biojector and 100 μg for needle plus EP),
delivered either as single or multiple injections, could in-
duce stronger immune responses than a considerably
lower dose (10 μg). Hence, BALB/c mice were immu-
nized twice with different doses and volumes of a HIV-1
Gag-encoding plasmid (pKCMVp37B) [10,36], either by
Biojector or with needle followed by EP.
Although we used a larger volume and thus higher
plasmid dose when immunizing with Biojector (100 μl),
than when immunizing with needle and EP (10 μl),
needle and EP induced higher magnitudes of IFN-γ se-
cretion when the DNA was delivered at multiple injec-

















































Figure 1 Impact of DNA vaccine dose and id delivery devices on imm
pKCMVp37B with either Biojector (BJ) or with needle followed by electropo
100 μl saline/injection. For needle plus EP, 10, 5 × 20 or 100 μg was deliver
assessed by IFN-γ ELISpot on splenocytes collected two weeks after the sec
to stimulate splenocytes. B) Binding antibodies to Gagp17/p24B were addr
immunization. Bars represent mean values. *Significant difference (p < 0.05)and low vaccine doses (p < 0.05) (Figure 1). This suggests
that EP is superior to Biojector to augment the immuno-
genicity of plasmid vaccines.
In terms of DNA dose, both Biojector and needle plus
EP immunized mice mounted similar magnitudes of im-
mune responses after immunization with the high
(1000 μg for Biojector and 100 μg for needle plus EP)
and the low (10 μg) dose (Figure 1). These results sug-
gest that a dose plateau was reached prior to or at the
low dose, that prevented further amplification of im-
mune responses, despite the use of two powerful DNA
delivery devices. No endotoxins were detected in neither
of the DNA preparations. Hence, we could exclude that
traces of endotoxins in the highly concentrated DNA
preparations (10 μg/μl) accounted for the limited im-
mune response that was induced in mice immunized
with the high dose DNA.
The limited cellular and humoral immune responses
induced by a high dose of DNA in both Biojector and
needle plus EP immunized mice appeared somewhat ele-
vated (p > 0.05) when the total amount of DNA was
divided and delivered as five injections on different in-
jection sites (5 × 200 μg for Biojector and 5 × 20 μg for
needle plus EP). Mice immunized with Biojector even
displayed significantly improved binding antibody titers
(p < 0.05). The superiority of multiple-site immunizations
has previously been observed after im needle immunizations
[28], and after id needle plus EP immunizations [25]. Here
we demonstrate that this phenomenon applies also for anti-
body responses after plasmid vaccine delivery with Biojector.
The addition of EP enhances immune responses of needle
and Biojector immunizations
As neither delivery by Biojector nor needle plus EP
could circumvent the observed dose plateau and elicit



















































unogenicity. BALB/c mice were immunized week 0 and 4 with
ration (EP). For Biojector, 10, 5 × 200 or 1000 μg DNA was delivered in
ed in 10 μl saline/injection. A) Cellular immune responses were
ond immunization. A peptide pool representing Gag p24B was used
essed by ELISA on serum collected two weeks post the last
. ns = no significant difference.
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bined effect of Biojector and EP was studied. BALB/c
mice were immunized twice with 10 μg pKCMVp37B by
needle (10 μg in 10 μl) or Biojector (10 μg in 100 μl),
with or without the addition of EP.
The results showed that needle and Biojector delivery,
with or without the addition of EP, induced similar levels
of IFN-γ and Gag-specific antibody titers (Figure 2). The
addition of EP to needle and Biojector immunizations
however enhanced the IFN-γ responses for both modes
of vaccine delivery, and antibody responses for needle
plus EP delivery (p < 0.05). Hence, although Biojector
has been shown to induce strong immune responses to
DNA vaccines, we show that when immunizing with a
low dose DNA, with or without the addition of EP, Bio-
jector does not induce stronger immune responses than
conventional needle delivery. Similar observations have
been reported when comparing the efficacy of needle
and Biojector DNA vaccine delivery id in pigs [6], or im
in cynomolgus monkeys [40]. However, a more concen-
trated DNA has been reported to correlate with stronger
immune responses [34,35]. The inability of Biojector
immunizations to induce stronger immune responses than
needle immunizations might thus be explained by the
more diluted DNA being injected by Biojector, as 100 μl is
the smallest volume that can be delivered by this device.
Injections with high DNA doses by a combination of
Biojector and EP induce luciferase-specific cell-mediated
immune responses
To further evaluate the combined effect of Biojector and
EP, we studied in vivo protein expression after Biojector


































Figure 2 Immune responses induced by different means of id DNA va
and delivered by needle or Biojector (BJ), respectively. Also mice immunize
included. Immunizations were done week 0 and 4. A) Cellular immune resp
weeks after the second immunization. A peptide pool representing Gag p2
serum collected at the same time point were determined by Gagp17/p24B
and **significant difference (p < 0.01). ns = no significant difference.with doses ranging from 10 to 1000 μg of a luciferase-
encoding plasmid (pVax-Luc) [13] or empty vector
(pKCMV). Subsequent luciferase expression in vivo was
measured using the Xenogen In Vivo Imaging System
(IVIS), which allows for a direct quantification of lucifer-
ase expression visualized as luminescent pixels after
cleavage of an ip injected luciferin substrate. Expression
was measured at 4, 8, 11, 18 and 25 days post injection
and immune responses were assessed by ELISA and
IFN-γ/interleukin-2 (IL-2) FluoroSpot [37] at day 25.
There was a decrease in luciferase expression at the
later time points in mice being injected with large doses
of DNA, as compared to mice receiving the low doses
(Figure 3A). Luciferase has been reported to be weakly
immunogenic [33,41] and Limberis et al. identified mur-
ine CD8+ T cell epitopes in luciferase [38]. Thus, the
dominant H2-Kd restricted GFQSMYTFV epitope was
used in this study to establish whether any luciferase-
specific CD8+ T cell responses were induced. The high-
est dose Luciferase-encoding plasmid induced higher
IFN-γ, IL-2 and IFN-γ/IL-2 responses than the lowest
dose (p = 0.03) (Figure 3B), and the level of antigen ex-
pression at day 8 correlated with the magnitude of cell-
mediated immune responses (p < 0.05) (Figure 3C). Fur-
thermore, the level of CD8+ T cell responses commonly
correlate with the ability of these T cells to clear trans-
fected cells [29,33,42]. The increased CD8+ T cell
responses did, however, not correlate with the decreased
luciferase-expression observed in Figure 3A (data not
shown), perhaps due to the limited levels of IFN-γ and
IL-2 responses induced even in the high dose group. No
luciferase-specific antibody responses were induced in


































ccine delivery. 10 μg pKCMVp37B was diluted in 10 or 100 μl saline
d with needle or Biojector followed by electroporation (EP) were
onses were assessed with IFN-γ ELISpot on splenocytes collected two
4B was used to stimulate splenocytes. B) Gag-specific IgG titers in
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Figure 3 In vivo luciferase expression following Biojector plus EP injections with escalating doses of DNA. BALB/c mice were immunized
once with Biojector followed by EP with 10-1000 μg of a luciferase-encoding plasmid (pVax-Luc) or empty vector diluted in 100 μl saline. A) 4, 8,
11, 18 and 25 days post DNA injections mice were injected ip with the D-luciferin substrate and expression of luciferase was monitored using the
Xenogen In Vivo Imaging System (IVIS). Results are shown as mean values (n = 4) and error bars represent standard error of the mean. B) At day
25, spleens were collected and IFN-γ, IL-2 and IFN-γ/IL-2 responses were assessed by FluoroSpot. The H2-Kd restricted GFQSMYTFV (luciferase) and
AMQMLKETI (Gag) peptides were used to assess luciferase-specific and unspecific cytokine secretion, respectively. Bars represent mean values for
the GFQSMYTFV peptide. C) Correlation between in vivo expression at day 8 and frequency of GFQSMYTFV-specific IFN-γ, IL-2 and IFN-γ/IL-2
secreting splenocytes at day 25. *Significant difference (p < 0.05).
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overcome dose restrictions to plasmid-encoded Gag
We next examined how the Biojector plus EP immunization
strategy with different doses applied for the Gag-encoding
DNA that was used in the two initial experiments.BALB/c mice were immunized once with doses ranging
from 10 to 1000 μg of pKCMVp37B or empty vector
(pKCMV), both mixed with 25 μg pVax-Luc to examine
the in vivo immunogenicity measured as the clearance
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Figure 4 Immunogenicity of Gag following Biojector plus EP immunizations with escalating doses of DNA. BALB/c mice were immunized
once with Biojector followed by EP with mixtures of 10–1000 μg pKCMVp37B or empty vector and 25 μg pVax-Luc diluted in 100 μl saline. A) 4,
8, 11, 18 and 25 days post DNA injections mice were injected ip with the D-luciferin substrate and expression of luciferase was monitored using
the Xenogen In Vivo Imaging System (IVIS). Results are shown as mean values (n = 4) and error bars represent standard error of the mean. B) At
day 25, spleens were collected and IFN-γ, IL-2 and IFN-γ/IL-2 responses were assessed by FluoroSpot. A Gag p24B peptide pool was used to
assess Gag-specific cellular immune responses, and the H2-Kd restricted GFQSMYTFV (luciferase) peptide was used to assess luciferase-specific
responses. Bars represent mean values for the Gag p24B peptide pool. C) Correlation between in vivo expression and frequency of Gag p24B
peptide pool-specific IFN-γ, IL-2 and IFN-γ/IL-2 secreting splenocytes at day 25. D) Antibody titers to Gag p17/p24B were assessed by ELISA on
serum collected 25 days post immunization. Bars represent mean values. *Significant difference (p < 0.05).
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luciferase-specific immune responses (Figures 3A and B).
The initial level of luciferase expression did not differ
significantly between groups (Figure 4A). An increase in
dose of pKCMVp37B was however associated with a
more rapid decline of luminescence. Results from the
FluoroSpot assay demonstrated that the mice receiving
the highest dose of Gag-encoding plasmid obtained sig-
nificantly stronger IFN-γ responses than mice immu-
nized with the lowest dose (p < 0.03) (Figure 4B). A
strong negative correlation between the frequency of
IFN-γ, IL-2 and IFN-γ/IL-2 responses and level of luci-
ferase expression was seen at 25 days post immunization
(p < 0.01) (Figure 4C), indicating that Gag-specific im-
mune responses can clear cells co-transfected with Gag-
and luciferase-encoding plasmids, and perhaps bystander
cells transfected with luciferase-encoding plasmids only
[43]. In addition, immunizations with the high doses of
Gag-encoding plasmid led to a more rapid and enhanced
reduction in luminescence than injections with high
doses of luciferase-encoding plasmid (Figure 3A and
Figure 4A), showing that Gag is more immunogenic
than luciferase. This was also seen in the FluoroSpot
assays (Figure 3B and Figure 4B).
Similar to the two initial studies with pKCMVp37B,
the Gag p24B peptide pool and the H2-Kd restricted
AMQMLKETI peptide stimulated comparable levels of
cellular immune responses in the ELISpot and Fluoro-
Spot assays (p < 0.05 for all groups) (data not shown),
demonstrating that the induced cell-mediated immune
responses, including those responsible for the clearance
of Gag-expressing cells, are mainly of CD8+ T cell na-
ture. With respect to antibody responses, the titers of
Gag-specific binding antibodies were enhanced as the
dose of Gag-encoding plasmid was increased, and the
mice receiving the highest dose elicited significantly
higher antibody titers than mice immunized with the
lowest dose (p = 0.03) (Figure 4D).
Biojector plus EP immunizations have previously been
studied in pigs [6]. That study showed that a combin-
ation of Biojector and EP lead to a more rapid induction
of antibody responses as compared to needle plus EP de-
livery. However, there was no difference in the magni-
tude of antibody titers. Here we demonstrate that the
combination of Biojector and EP can overcome the
observed dose restriction of a Gag-encoding plasmid
and enhance immune responses when the DNA vaccine
dose is increased. This is most probably a consequence
of enhanced transfection efficacy of id delivery, in part
by targeting a large number of cells with Biojector, and
in part by improved cellular uptake when adding EP. We
assume that the observed antigen expression and subse-
quent immune response indeed are located in the der-
mal layer of the skin and not in underlying muscle sincewe use a Biojector device that is adjusted for id delivery
to mice. Moreover, we have previously shown that ap-
proximately 1000-fold less DNA is located in the under-
lying muscle as compared to the injected skin after
Biojector plus EP immunizations in mice [44].
Conclusions
In summary, the present findings demonstrate that the
combination of Biojector and EP can overcome the
observed dose restriction of a DNA vaccine and enhance
immune responses when the dose is increased. Further-
more, we show that levels of antigen expression correl-
ate with the frequency of IFN-γ and IL-2 secretion, and
that the clearance of antigen expression correlates with
the magnitude of IFN-γ responses to CD8+ T cell epi-
topes. Although the high concentration and thus high
doses of DNA used in this study are too high to translate
directly into human settings, these comparisons show
that these two modes of optimized DNA vaccine delivery
can act together to overcome dose restriction of a plas-
mid DNA vaccine.
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